LAB - Standard BioTools Inc. Stock Price, Fair Value and News

$1.86+0.03 (+1.64%)

Delayed as of 26 Dec 2024, 11:29 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

LAB Price Action

Last 7 days

-17.2%

Last 30 days

14.4%

Trailing 12 Months

-8.0%

LAB RSI Chart

LAB Valuation

Market Cap

681.2M

Price/Earnings (Trailing)

-5.47

Price/Sales (Trailing)

4.37

EV/EBITDA

-4.28

Price/Free Cashflow

-4.59

LAB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

LAB Fundamentals

LAB Revenue

Revenue (TTM)

155.9M

Rev. Growth (Yr)

77.27%

Rev. Growth (Qtr)

20.87%

LAB Earnings

Earnings (TTM)

-124.6M

Earnings Growth (Yr)

-28.29%

Earnings Growth (Qtr)

41.08%

LAB Profitability

EBT Margin

-79.83%

Return on Equity

-25.46%

Return on Assets

-18.28%

Free Cashflow Yield

-21.8%

LAB Investor Care

Shares Dilution (1Y)

368.87%

Diluted EPS (TTM)

-0.7

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	126.8M	136.3M	155.9M	0
2023	96.6M	105.5M	105.2M	106.3M
2022	124.3M	112.0M	109.2M	97.9M
2021	143.3M	148.3M	136.9M	130.6M
2020	114.7M	112.6M	126.0M	138.1M
2019	117.8M	119.6M	117.1M	117.2M
2018	101.7M	104.2M	108.4M	113.0M
2017	101.0M	96.7M	99.3M	101.9M
2016	117.0M	116.5M	110.1M	104.4M
2015	117.5M	118.5M	117.5M	114.7M
2014	82.4M	92.5M	103.8M	116.5M
2013	55.9M	60.5M	66.0M	71.2M
2012	45.1M	47.5M	49.7M	52.3M
2011	35.5M	38.1M	40.2M	42.9M
2010	0	28.1M	30.8M	33.6M
2009	0	0	0	25.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Standard BioTools Inc.

Standard BioTools Inc., together with its subsidiaries, creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

CEO	Dr. Michael Egholm Ph.D.
WEBSITE	fluidigm.com
SECTOR	Healthcare
INDUSTRY	Diagnostics & Research
EMPLOYEES	523

Standard BioTools Inc. Frequently Asked Questions

What is the ticker symbol for Standard BioTools Inc.? What does LAB stand for in stocks?

LAB is the stock ticker symbol of Standard BioTools Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Standard BioTools Inc. (LAB)?

As of Tue Dec 24 2024, market cap of Standard BioTools Inc. is 681.23 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LAB stock?

You can check LAB's fair value in chart for subscribers.

Is Standard BioTools Inc. a good stock to buy?

The fair value guage provides a quick view whether LAB is over valued or under valued. Whether Standard BioTools Inc. is cheap or expensive depends on the assumptions which impact Standard BioTools Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LAB.

What is Standard BioTools Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Dec 24 2024, LAB's PE ratio (Price to Earnings) is -5.47 and Price to Sales (PS) ratio is 4.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LAB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Standard BioTools Inc.'s stock?

In the past 10 years, Standard BioTools Inc. has provided -0.252 (multiply by 100 for percentage) rate of return.